Clinical Trial Update: Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study assessing safety and pharmacokinetics of BGB-3111 in subjects with B-cell lymphoid malignancies completed; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoid Malignancies

Drugs mentioned

• BGB-3111 (BGB-3111)

Snippet

Sponsor: BeiGene | Conditions: B-cell Malignancies | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-04-27